Breaking Finance News

Inovio Pharmaceuticals Inc (NASDAQ:INO) has been downgraded to Sell in a report by Zacks Investment Research today.

Just yesterday Inovio Pharmaceuticals Inc (NASDAQ:INO) traded 1.95% higher at $9.21. Inovio Pharmaceuticals Inc’s 50-day average is $9.14 and its two hundred day average is $9.36. With the last stock price down 0.33% from the two hundred day moving average, compared to the S&P 500 Index which has fallen -0.01% over the date range. 682,233 shares of the stock traded, down from ann average trading volume of 1,478,510.

Zacks Investment Research has downgraded Inovio Pharmaceuticals Inc(NASDAQ:INO) to Sell in a statement released Tuesday September 20 2016.

Recent Performance Graph:

Inovio Pharmaceuticals Inc (NASDAQ:INO)

A total of 5 analysts have issued a ratings update on Inovio Pharmaceuticals Inc. Two firms rate the stock a strong buy, three analysts rate the stock a buy, 0 firms rate the stock a hold, 0 rate the stock to underperform, and finally 0 analystsrate the stock as sell with an average target price of $18.60

Inovio Pharmaceuticals Inc has a 52 week low of $4.50 and a one-year high of $11.69 . INO’s market capitalization is presently $0.0.

Brief Synopsis On Inovio Pharmaceuticals Inc (NASDAQ:INO)

Inovio Pharmaceuticals, Inc. (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, and the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.